Vitaxin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-v beta-3 integrin |
| Clinical data | |
| Trade names | Vitaxin |
| ATC code |
|
| Identifiers | |
| DrugBank | |
| ChemSpider |
|
  (what is this?) | |
Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]
Vitaxin is safe for humans. It has little effect on advanced cancer.[3]
References
- ^ Cherrington JM, Strawn LM, Shawver LK (2000). Vande Woude GF, Klein G (eds.). "New paradigms for the treatment of cancer: the role of anti-angiogenesis agents". Advances in Cancer Research. 79. Academic Press: 1–38 (27). doi:10.1016/s0065-230x(00)79001-4. ISBN 978-0-12-006679-7. PMID 10818676.
{{cite journal}}: CS1 maint: periodical has ISBN (link) - ^ Wilder RL (November 2002). "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases. 61 (Suppl 2): ii96–ii99. doi:10.1136/ard.61.suppl_2.ii96. PMC 1766704. PMID 12379637.
- ^ a b McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. (November 2005). "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research. 11 (21): 7851–7860. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408. S2CID 33227412.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.